AbbVie swings to Q4 loss amid Cerevel impact; sets in-line guidance
by
Contributor since / Followers
Contributor since / Followers
3 months ago
Michael Vi/iStock Editorial via Getty Images
AbbVie (NYSE:ABBV) traded higher in the premarket on Friday after setting its 2025 earnings outlook in line with expectations even as it reported a loss of $22M for Q4 driven by a $3.5B impairment charge related to its Cerevel